← Back to Search

Stem Cell Therapy

treatment with A3 SVF for Osteoarthritis

N/A
Waitlist Available
Led By John Huh, MD
Research Sponsored by Institute of Regenerative and Cellular Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

To purpose of this study is to determine if treatment with SVF (Stromal Vascular Fraction) has an effect on pain and inflammation associated with Osteoarthritis.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: treatment with A3 SVFExperimental Treatment1 Intervention
These patients that have been treated. The control patients that have not been treated.

Find a Location

Who is running the clinical trial?

Institute of Regenerative and Cellular MedicineLead Sponsor
Barbara KrutchkoffStudy ChairInstitute of Regenerative and Cellular Medicine
John Huh, MDPrincipal InvestigatorICMS
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top